These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19125002)

  • 1. Chemosensitivity and chemoresistance testing in ovarian cancer.
    Cree IA
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
    Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
    Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
    Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
    O'Meara AT; Sevin BU
    Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
    Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.
    Kurbacher CM; Cree IA
    Methods Mol Med; 2005; 110():101-20. PubMed ID: 15901931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cancer-associated gene abnormalities and chemosensitivity].
    Sakamoto M; Umayahara K; Sakamoto H; Kawasaki K; Suehiro Y; Kunugi T; Akiya T; Iwabuchi H; Sakunaga H; Muroya T; Kikuchi Y; Sugishita T; Tenjin Y; Gray JW; Tanaka T
    Gan To Kagaku Ryoho; 1998 Oct; 25(12):1819-31. PubMed ID: 9797804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL; Peng ZL; Liu SL
    Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay.
    Hunter EM; Sutherland LA; Cree IA; Dewar JA; Preece PE; Wood RA; Linder D; Andreotti PE
    Eur J Surg Oncol; 1993 Jun; 19(3):242-9. PubMed ID: 8314382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
    Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
    Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples.
    Ng TY; Ngan HY; Cheng DK; Wong LC
    Gynecol Oncol; 2000 Mar; 76(3):405-8. PubMed ID: 10684718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
    Shi W; Gu M; Liang L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.
    Andreotti PE; Linder D; Hartmann DM; Cree IA; Pazzagli M; Bruckner HW
    J Biolumin Chemilumin; 1994; 9(6):373-8. PubMed ID: 7879653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Result of individualized chemotherapy with a newly developed in vitro chemosensitivity testing in ovarian cancer].
    Iijima N; Sekiya S; Tokita H; Oosaki T; Takamizawa H
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Oct; 43(10):1323-8. PubMed ID: 1955784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response.
    Ness RB; Wisniewski SR; Eng H; Christopherson W
    Anticancer Res; 2002; 22(2B):1145-9. PubMed ID: 12168915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of ornithine decarboxylase as a measure of chemosensitivity testing.
    Bachrach U
    Methods Mol Med; 2005; 110():197-211. PubMed ID: 15901937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
    Gerçel-Taylor C; Ackermann MA; Taylor DD
    Anticancer Res; 2001; 21(4A):2761-8. PubMed ID: 11724352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A chemosensitivity test to individualize intravesical treatment for non-muscle-invasive bladder cancer.
    Gazzaniga P; Gradilone A; de Berardinis E; Sciarra A; Cristini C; Naso G; di Silverio F; Frati L; Aglianò AM
    BJU Int; 2009 Jul; 104(2):184-8. PubMed ID: 19154503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
    Kurbacher CM; Grecu OM; Stier U; Gilster TJ; Janát MM; Untch M; Konecny G; Bruckner HW; Cree IA
    Recent Results Cancer Res; 2003; 161():221-30. PubMed ID: 12528810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consolidation therapy in ovarian cancer: where do we stand?
    Dearnley DD; McMeekin DS
    Curr Opin Obstet Gynecol; 2006 Feb; 18(1):3-7. PubMed ID: 16493252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.